[Methadone and sleep apnea syndrome].
BACKGROUND
Sleep apnea syndrome occurs when, during sleep, breathing stops for 10 seconds or longer, with an index of 5 times or more an hour. It is clinically characterized by loud snoring at night, continuous or interrupted by pauses followed by loud breathing. Sleep is fitful, broken by arousals, and yields little rest. There is daytime excessive sleepiness with repeated involuntary falling asleep, often unknown by the subject.


METHODS
In this article, we describe an observation of central sleep apnea syndrome in a female patient receiving an opiate replacement therapy.


METHODS
An analysis of the before and after methadone withdrawal polysomnograhic tracing was done for this patient.


RESULTS
This diagnosis etiology and physiopathology are critically approached. Clinicians should be careful in treating induced sleep disorders in such patients.


CONCLUSIONS
Prescribing benzodiazepines during an opiate withdrawal of the methadone type is not recommended when central apnea occurs.
Durst
Philippe
P
Centre Hospitalier Sainte Marie, Réseau ERAHSM, Privas, France.
Palazzolo
Jérôme
J
Peyrelong
Jean-Pierre
JP
Berger
Michel
M
Chalabreysse
Michel
M
Billiard
Michel
M
Vialle
André
A
D000328:Adult; D001921:Brain / Q000187:drug effects; D003000:Clonidine / Q000009:adverse effects / Q000627:therapeutic use; D019970:Cocaine-Related Disorders / Q000534:rehabilitation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006556:Heroin Dependence / Q000534:rehabilitation; D006801:Humans; D006919:Hydroxyzine / Q000009:adverse effects / Q000627:therapeutic use; D008691:Methadone / Q000009:adverse effects* / Q000627:therapeutic use; D008728:Methotrimeprazine / Q000009:adverse effects / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D017286:Polysomnography / Q000187:drug effects; D020182:Sleep Apnea, Central / Q000139:chemically induced*; D012894:Sleep Stages / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014291:Trimeprazine / Q000009:adverse effects / Q000627:therapeutic use
D006919:Hydroxyzine; D017374:Paroxetine; D014291:Trimeprazine; D008728:Methotrimeprazine; D003000:Clonidine; D008691:Methadone